Company Shares of T2 Biosystems (NASDAQ:TTOO) Drops by -32.23%

T2 Biosystems (NASDAQ:TTOO) : During the past 4 weeks, traders have been relatively bearish on T2 Biosystems (NASDAQ:TTOO), hence the stock is down -41.17% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -33.09% relative to the S&P 500. The 4-week change in the price of the stock is -40.23% and the stock has fallen -32.23% in the past 1 week.

The company shares have dropped -68.48% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $17.10 and the one year low was seen on Jul 8, 2016. The 50-Day Moving Average price is $8.47 and the 200 Day Moving Average price is recorded at $8.97.

The stock has recorded a 20-day Moving Average of 36.89% and the 50-Day Moving Average is 38.32%.


T2 Biosystems (NASDAQ:TTOO): On Fridays trading session , Opening price of the stock was $6.02 with an intraday high of $6.71. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.11. However, the stock managed to close at $5.32, a loss of 30.09% for the day. On the previous day, the stock had closed at $7.61. The total traded volume of the day was 796,270 shares.

In an insider trading activity, The officer (SVP of Corporate Development), of T2 Biosystems, Inc., Dhanda Rahul had unloaded 3,589 shares at $8.16 per share in a transaction on June 30, 2016. The total value of transaction was $29,286. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

T2 Biosystems, Inc. is an in vitro diagnostics company that has developed a technology platform offering an alternative to diagnostic methodologies. The Companys T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Companys initial development efforts target sepsis, hemostasis and Lyme disease, areas of significant unmet medical need. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The initial panels designed to run on T2Dx are T2Candida and T2Bacteria, which are focused on identifying life-threatening pathogens associated with sepsis.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.